| |
GT3 Progress quickly - HCV/HIV Coinfected Patients & Switching ARTs - GT3 Daclatasvir/SOF 24 Weeks Model 95% SVR
|
| |
| |
HCV genotype 3 is associated with an increased risk of cirrhosis and hepatocellular cancer in a national sample of U.S. Veterans with HCV - (07/16/14)
"Our findings have implications that involve the entire spectrum of care from antiviral treatment to prevention and screening in patients with HCV genotype 3 infection. Given the accelerated progression to advanced liver disease, patients with HCV genotype 3 may serve as a high-risk group that will need to be prioritized in the era of new antiviral treatments. Unfortunately, SVR rates with the all-oral regimen combination of sofosbuvir and ribavirin may be lower in patients with genotype 3 compared to those with genotype 2 infection.[11, 12]..........The risk of cirrhosis and HCC was 31% (adjusted HR = 1.31, 95% CI = 1.22-1.39) and 80% (adjusted HR = 1.80, 95% CI = 1.61-2.03) greater in patients with HCV genotype 3 compared to genotype 1......our data show that a substantial proportion of patient with genotype 3 infection already have developed cirrhosis (24.6%); these patients will likely remain at risk for HCC regardless of whether they receive or respond to antiviral treatment. Thus, HCV genotype 3 infection may have a major role to screen for patients who are at an increased risk for HCC......"HCV genotype 3-associated hepatic steatosis results from a direct viral effect that is independent of other predisposing conditions such as overweight, diabetes, or alcohol use.[16-18] Indeed, patients with HCV genotype 3 in our cohort were less likely to be obese or to have diabetes-findings that were consistent with previous reports.[9, 18] Hepatic steatosis may underlie the accelerated fibrosis observed in genotype 3 infection.[18, 19]"
ClinPharmWk: Readying HIV/HCV Coinfected Patients for HCV Treatment: Occurrence and Management of Antiviral Interactions....[can patients switch their HIV regimen?] - (06/01/15)
ClinPharmWk: Population Viral Kinetic Modeling: SVR Prediction in HCV GT-3 Cirrhotic Patients With 24 Weeks of Daclatasvir + Sofosbuvir Administration - (05/29/15)
|
|
| |
| |
|
|
|
